Medical Doctor, Cardiologist, Ph.D. Fellow Intravascular Imaging Core Laboratory, ISAResearch Center, German Heart Center Munich, Technical University of Munich
Munich, Germany
Joined December 2011
- Tweets18
- Following126
- Followers58
- Likes145
What's the best strategy for calcified coronary lesions? NMA of 22 RCTs (~5,000 pts): RA, SHPB, IVL & modified balloons outperform NCB on stent area. No clinical benefit yet — likely due to underpowered trials. More RCTs needed.
onlinelibrary.wiley.com/doi/…
Fiorenzo Simonetti retweeted
Recurrent TR after T-TEER can limit TTVR when central clips obstruct valve delivery. The ELASTA-T technique enables controlled leaflet detachment to facilitate TTVR.
Read our step-by-step expert review on this novel strategy. #Cardiology
eurointervention.pcronline.c…
@FiorenzoSimo @TRheude @StarneckerF @XhepaErion @MichaelJoner3
Fiorenzo Simonetti retweeted
NEW ISSUE OUT 🔥🔥
- An Expert Review on the ELASTA-T technique for transcatheter tricuspid valve replacement;
- Transcatheter therapies in aortic regurgitation;
- Renal function and antithrombotic therapy in AF-CAD;
- Device depth and flow dynamics in left atrial appendage closure;
- Design and rationale of the NAPT-LAAC trial;
and more
#Cardiology #cardiotwitter
eurointervention.pcronline.c…
@MartineGilard
@DIDIERRomain3
@laurenranard
@MichaelJoner3
@dukwoo_park
@freixa_xavier
@FiorenzoSimo
@Albenquegrgoire
@JordiMill
Fiorenzo Simonetti retweeted
In this study, cangrelor provided effective platelet inhibition during PCI, with low HRPR rates during infusion. Transition to oral P2Y12 inhibitors—particularly clopidogrel—was associated with a transient increase in high residual platelet reactivity. #EIJBestOf
#InterventionalCardiology #Cangrelor #AntiplateletTherapy
🔗eurointervention.pcronline.c…
@GargiuloG83
@espogiov @CirilloPlinio @DSCastiello @IForzano46837 @d_florimonte @FiorenzoSimo @me_canonico @llddss80 @franzone_anna @piccoloraf @vlgmrc
Fiorenzo Simonetti retweeted
From trial to real-world care
In the Danish registry recently published, @JacobsenRavn et al. showed prasugrel’s advantage over ticagrelor after PCI for MI — confirming ISAR-REACT 5.
@adnan_kastrati & @FiorenzoSimo discuss how real-world evidence closes the loop from RCTs to everyday practice
Editorial: shorturl.at/4ARwQ
Main Paper: tinyurl.com/8dkyx6s8
Fiorenzo Simonetti retweeted
Bleeding Risk: Using DAPT Score to Minimize Complications While Maintaining Efficacy
@piccoloraf | @FiorenzoSimo
hemostasistoday.com/insight/…
#BleedingRisk #Cardiology #ClinicalTrial #DAPTScore #Health #Hematology #Hemostasis #PatientCare #HemostasisToday #Medicine #PersonalizedMedicine
#MedED #MedX
Fiorenzo Simonetti retweeted
A personalized DAPT was superior to standard DAPT after PCI.📌Here are the slides presented at: #ESCCongress @mmamas1973 @mirvatalasnag @rwyeh @djc795 @CMichaelGibson @SripalBangalore @Costa_F_8 @pash22 @Ahmed43101178 @Hragy @SABOURETCardio @drjohnm @espogiov @JACCJournals
In patients undergoing #PCI, a personalized #DAPT duration from 3 to 24 months led to a lowered risk of net adverse clinical events than standard care consisting of 12 months of DAPT. jacc.org/doi/10.1016/j.jacc.…
#JACC #ESCCongress #WCCardio @piccoloraf @DFCapodanno
Happy to see the presentation of the results of the PARTHENOPE Trial, together with the simultaneous publication in #JACC
bit.ly/47pBB0l
This achievement represents years of dedication and strong collective effort.
I’m glad to have been part of this team.
#ESCCongress
Fiorenzo Simonetti retweeted
Are you performing right cath after TTVR?
EJHF: First insights into the impact of TR elimination on right heart:
Immediate RAP reduction ⬇️
Increased systolic RV/PA pressure⬆️ and PAPi ⬆️
Data From Bern by Fabien Praz
🔗 doi.org/10.1002/ejhf.3781
@EJHFEiC #CardioTwitter
Can OCT guide treatment for in-stent restenosis?
While essential in complex PCI, its role in this setting remains unclear.
The ISAR-DESIRE 5 randomized trial will provide new evidence. #OCT #ISR #Intravascularimaging #interventionalcardiology
rdcu.be/ew8ap
Fiorenzo Simonetti retweeted
The PARTHENOPE trial addresses the ongoing challenge of balancing restenosis, stent thrombosis, and bleeding in coronary interventions. Decades of advancements point to the need for personalized strategies in antiplatelet therapy. Read the editorial: ow.ly/JIEX50UIVJ9
Fiorenzo Simonetti retweeted
The PARTHENOPE trial showed that polymer-free amphilimus-eluting stents (AES) are non-inferior to biodegradable-polymer everolimus-eluting stents (EES) for PCI outcomes at 1 year. AES outcomes were comparable overall, with results adding to evidence on DES options. Full details: shorturl.at/u98iO #Cardiology #PCI #EAPCI
@piccoloraf
Fiorenzo Simonetti retweeted
Our randomized trial found similar platelet inhibition with ticagrelor 60 vs. 90 mg in elderly patients undergoing PCI during the early phase of ACS
#CardioTwitter @escardio @TCTMD @PCRonline @SCAI @MattiaGalli10 @FeliceGragnano @EditorEHJCVP @UninaIT
academic.oup.com/ehjcvp/arti…
Fiorenzo Simonetti retweeted
@piccoloraf Mortality risk was increased in patients with 4th UDMI periprocedural MI fulfilling 2 or 3 criteria, but not in those meeting 1 criterion. These findings may suggest a need to refine the fourth UDMI periprocedural MI definition.
jacc.org/doi/10.1016/j.jacc.…
Fiorenzo Simonetti retweeted
📢Check out today's #Highly_Cited Paper
"Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review"
👨🔬 Attilio Leone et al.
🏫University of Naples Federico II @UninaIT
👍 Article Views 4255; Citations 8
🍀mdpi.com/1795620
@MDPIOpenAccess @MediPharma_MDPI
Fiorenzo Simonetti retweeted
Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry via @EuroInterventio eurointervention.pcronline.c… proud of this! Cangrelor as effective and safe option for COMPLEX PCI but attention to transition to oral P2Y12i...
